---
title: "CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold Rating at Bank of China"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/280856491.md"
description: "CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold rating by Bank of China with a price target of HK$9.10 on March 26, following a close of HK$8.16. UBS also assigned a Hold rating on March 25. Meanwhile, CMB International Securities maintained a Buy rating on the same day."
datetime: "2026-03-28T00:47:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280856491.md)
  - [en](https://longbridge.com/en/news/280856491.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280856491.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/280856491.md) | [繁體中文](https://longbridge.com/zh-HK/news/280856491.md)


# CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold Rating at Bank of China

CSPC Pharmaceutical Group received a Hold rating and a HK$9.10 price target from Bank of China analyst on March 26. The company’s shares closed last Tuesday at HK$8.16.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

In addition to Bank of China, CSPC Pharmaceutical Group also received a Hold from UBS’s Anita Wei in a report issued on March 25. However, on March 26, CMB International Securities maintained a Buy rating on CSPC Pharmaceutical Group (Other OTC: CHJTF).

### 相关股票

- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md)
- [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-CN/quote/159570.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md)
- [CSPC PHARMA (01093.HK)](https://longbridge.com/zh-CN/quote/01093.HK.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md)
- [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/zh-CN/quote/562050.CN.md)
- [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/zh-CN/quote/520500.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md)

## 相关资讯与研究

- [CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates](https://longbridge.com/zh-CN/news/280415449.md)
- [CSPC Profit Slips but Dividend Rises as China Pharma Shifts to Innovation](https://longbridge.com/zh-CN/news/280418974.md)
- [CSPC Wins China Approval for New Aprepitant Injection to Strengthen Antiemetic Portfolio](https://longbridge.com/zh-CN/news/280149874.md)
- [Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.](https://longbridge.com/zh-CN/news/280502605.md)
- [Grand Pharmaceutical Lifts Revenue, Boosts Innovative Mix Amid Margin Pressure](https://longbridge.com/zh-CN/news/280678162.md)